The advisor

Equitable Life has announced that effective January 1, 2017, two intranasal corticosteroids products, Flonase® and Nasacort®, along with their generic versions, will no longer be covered in Saskatchewan, as over-the-counter versions of these medications are now available for purchase without a prescription. Fluticasone 50ug/dose nasal spray (Flonase® and generics); and Triamcinolone 55ug/dose nasal spray ( Nasacort®… Read More >

Read more
Share:

This week, Manulife has announced that Repatha, an injectable drug to treat high cholesterol, has been approved to be listed on its drug plans after undergoing its drug evaluation program. Last year, Manulife introduced DrugWatch to evaluate new drugs coming into the market as an oversight measure to help private drug plans better manage the escalating costs of… Read More >

Read more
Share:

Effective October 4, Equitable Life has announced that topical creams and ointments containing 1% hydrocortisone or less will no longer be eligible for coverage under drug plans that exclude natural health products. They will still be eligible under provincial mimic plans where the province covers them. Health Canada’s decision this past year to reclassify these… Read More >

Read more
Share:

The Advisor Newsletters